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Aims Diabetes mellitus (DM) is associated with poor clinical outcomes in humans with peripheral arterial disease (PAD) and
in pre-clinical models of PAD, but the effects of glycaemic control are poorly understood. We investigated the effect of
glycaemic control on experimental PAD in mice with Type 1 DM and explored the effects of hyperglycaemia on vascular
endothelial growth factor receptor 2 (VEGFR2) expression in ischaemia.
Methods
and results
Hind limb ischaemia was induced in non-diabetic, untreated Type 1 DM, and treated Type 1 DM mice. We assessed
perfusion recovery, capillary density, VEGFR2 levels, and VEGFR2 ubiquitination in ischaemic hind limbs. We found that
untreated Type 1 DM mice showed impaired perfusion recovery, lower hind limb capillary density 5 weeks post-ischaemia,
and lower VEGFR2 protein in Day 3 post-ischaemic hind limbs when compared with non-DM controls. Treated Type 1 DM
mice had perfusion recovery, capillary density, and VEGFR2 protein levels comparable with that of non-diabetic mice at the
sametimepoints.Treatmentwithanti-VEGFR2antibodynegated that the improvedperfusionrecoverydisplayedby treated
Type 1 DM mice. In ischaemic Type 1 DM hind limbs and endothelial cells exposed to simulated ischaemia, high glucose
impaired VEGFR2 expression and was associated with increased VEGFR2 ubiquitination. Inhibition of the ubiquitin–
proteasome complex restored normal endothelial VEGFR2 expression in simulated ischaemia.
Conclusion Hyperglycaemia in Type 1 DM impairs VEGFR2 protein expression in ischaemic hind limbs, likely due to increased
ubiquitination and degradation by the proteasome complex. Glycaemic control allows normal levels of VEGFR2 in
ischaemia and improved perfusion recovery.
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1. Introduction
Peripheral arterial disease (PAD) refers to atherosclerosis occurring
in vascular beds outside the heart, and the lower extremities are the
most common sites of PAD. Both Type 1 and Type 2 diabetic mellitus
(DM) patients are at an increased risk of developing PAD.1,2 Compared
with patients with PAD but no DM, individuals with PAD with
concurrent DM have a seven-fold higher risk of critical limb ischaemia
and a five-fold higher risk of amputation.3,4 While individuals with
diabetes may develop PAD at an earlier age and thus have had PAD
for a longer time than PAD patients without DM, it is more likely
that DM results in impairment in the adaptation to the vascular
occlusions resulting in a greater severity of disease. Despite the
well-established importance of glycaemic control in improving
outcomes of certain diabetes complications (e.g. retinopathy and
nephropathy),5 the role of glycaemic control in improving PAD out-
comes is poorly understood.
The mouse hind limb ischaemia (HLI) model that involves surgical
ligation and excision of the femoral artery has been used extensively
to study processes that are involved in perfusion recovery following
vessel occlusion.6 Using this model, several studies, including ones
from our laboratory, have shown that perfusion recovery is impaired
in mice with DM (Table 1). This pre-clinical model ‘creates’ PAD at the
same time and to the same extent across different mouse groups,
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which allows the investigation of mechanisms that are involved in
perfusion recovery.
Angiogenesis is the growth of new vessels from pre-existing vascular
structures. Vascular endothelial growth factor (VEGF) is a well-known
pro-angiogenic agent involved in blood vessel growth during develop-
ment and post-natal angiogenesis in the adult.14 The biological effects
of VEGF are mediated through binding to its two main receptors, such
as VEGF receptors 1 and 2 (VEGFR1 and VEGFR2),14– 16 which are high-
affinity receptor tyrosine kinases. VEGFR1 has a 10-fold higher binding
affinity for VEGF than VEGFR2 but a 10-fold lower tyrosine kinase
activity.14–16 The VEGF/VEGFR pathway plays a critical role in perfusion
recovery following HLI, but VEGFR2 is considered the dominant
receptor that mediates post-natal angiogenesis.14–16 Prior studies
investigating the role of the VEGF/VEGFR in impaired perfusion recov-
ery in diabetes have focused primarily on impaired vascular endothelial
growth factor A (VEGFA) expression in Type 1 DM (summarized in
Table 1). We are not aware of any study that has explored the possibility
that impaired VEGFR2 expression in ischaemic hind limbs of Type 1 DM
mice may be associated with impaired perfusion recovery. Additionally,
normalizing hyperglycaemia in mice with Type 1 DM and exploring the
impact on perfusion recovery following experimental PAD have not
been studied.
2. Methods
For more details, see Supplementary material online.
2.1 Mice and model of Type 1 diabetes
All mice (C57BL/6 and C57BL/6J-Ins2Akita) were obtained from the Jackson
Laboratory (Bar Harbor, ME, USA) either directly or bred internally from
parental strains obtained from the Jackson Laboratory (more details in Sup-
plementary material online). The C57BL/6J-Ins2Akita is the Ins2Akita strain on a
C57BL/6 background. The Ins2Akita is a previously described mouse model of
Type 1 diabetes17 (see Supplementary material online, Methods for details of
blood glucose assessment).
2.2 Experimental PAD/HLI and perfusion
recovery
HLI was achieved by unilateral femoral artery ligation and excision as
described previously.6 Blood flow in the ischaemic and contralateral non-
ischaemic limbs were measured by laser Doppler perfusion imaging as
described previously.11 Controls were strain, age, and sex matched.
2.3 RNA, quantitative PCR, and protein analysis
Total RNA was isolated and used for real-time quantitative RT–PCR as pre-
viously described.18 Total hind limb muscle protein lysates were obtained as
previously described.11 Levels of VEGFR2 were analysed by ELISA following
the manufacturer’s protocol (R&D Systems, Minneapolis, MN, USA) and
were normalized to the total protein from each hind limb muscle lysate.
A fold increase in expression reflects the normalized expression in the ischae-
mic hind limb compared with that in the non-ischaemic hind limb. VEGFR2 in
humanumbilical veinendothelial cells (HUVECS,nohigher thanPassage8)was
analysed by western blotting as previously described11 using an anti-VEGFR2
antibody 55B11 (Cell Signaling, Danvers, MA, USA). The extent of VEGFR2
ubiquitination was analysed by immunoprecipitation (IP) of VEGFR2 from
cells and muscle lysates followed by western blotting with anti-ubiquitin anti-
body FK2 (Enzo Life Sciences, Farmingdale NY, USA; see Supplementary ma-
terial online, Methods). To inhibit the ubiquitin–proteasome degradation
pathway, cells were pre-incubated with 5 nmol/L of epoxomycin (Cayman
Chemical, Ann Arbor, MI, USA) 24 h prior to simulated ischaemia.
2.4 Cell line and culture
HUVEC and endothelial cell growth medium (ECGM) were obtained from
Cell Applications, Inc. (San Diego, CA, USA). ECGM was supplemented
with 10% fetal bovine serum. In vitro simulation of ischaemia was achieved
as previously described,19 with slight modifications (see Supplementary ma-
terial online, Methods).
2.5 Capillary density and
immunohistochemistry
In the ischaemic and non-ischaemic hind limb muscles, capillaries were iden-
tified using CD31 staining or by endogenous alkaline phosphatase as previ-
ously described.20
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Table 1 Studies showing impaired perfusion recovery in DM1 and DM2mice following HLI surgery
References Primary focus DMmodel VEGF/VEGF receptor
analysed
Therapeutic
intervention
Hazarika et al.7 Impaired angiogenesis in DM2 DM2 ¼ HFD VEGFA, R1, and R2 None
Rivard et al.8 Rescue impairment of angiogenesis by VEGFA DM1 ¼ NOD VEGFA Yes (VEGFA)
Tamarat et al.9 Elevated advanced glycation end products as a mechanism for
impaired angiogenesis in DM
DM1 ¼ STZ Not evaluated Yes (amino guanidine)
Ebrahimian et al.10 ROS as a mechanism for impaired perfusion recovery in DM1 DM1 ¼ STZ VEGFA Yes (N acetyl-1-cysteine)
Li et al.11 VEGFA activating transcription factor can improve perfusion
recovery DM2
DM2 ¼ HFD VEGFA,R1,R2 (mRNAonly) Transcription factor
activating VEGFA
Thangarajah12 Impaired HIF-1 alpha expression in DM2 DM1 ¼ STZ
DM2 ¼ db/db
Not evaluated Deferoxamine
Moriya et al.13 Impaired PDGF-C, Nrp1 and
Nrp2 in DM1
DM1 ¼ STZ Not evaluated PDGF-C and VEGFA
Summary of recent studies showing impaired perfusion recovery and potential mechanisms of impairment in Type 1 and Type 2 DM mice following HLI. All studies show impaired perfusion
recovery in DM and some showed impaired expression of VEGFA. None addressed the effects of controlling hyperglycaemia on perfusion recovery or effects of hyperglycaemia or DM1 on
VEGFR2 protein expression.
DM1, type 1 diabetes mellitus; DM2, type 2 diabetes mellitus; Nrp1, neuropilin 1; Nrp2, neuropilin 2; PDGF-C, platelet derived growth factor C; ROS, reactive oxygen species; STZ,
streptozotocin; VEGFA, vascular endothelial growth factor A.
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2.6 Statistical analysis
All measurements were expressed as mean+SEM. Statistical comparisons
betweentwogroups (e.g. treatedvs. untreated) at a specific timepointwasper-
formed with the independent Student’s t-test or x2 where appropriate. Com-
parison of more than two groups at a time was performed with analysis of
variance. In all cases, a P-value of,0.05 was considered statistically significant.
3. Results
3.1 Effects of hyperglycaemia on perfusion
recovery, limbnecrosis, and capillary density
following experimental PAD
Untreated Type 1 DM mice were allowed 12 weeks of hyperglycaemia ex-
posure, resulting in significantly higher HbA1c levels (10.5+1.2, n ¼ 62)
than non-diabetic controls (4.4+0.4, n ¼ 56). Following HLI in Type 1
DM mice, 12.5% of the mice showed Stage 2 necrosis compared with 0%
in non-DM controls (n ¼ 16 and 8, respectively, not statistically significant
using a x2 test). Additionally, perfusion recovery over time was impaired in
theuntreatedType1DMmice (Figure1A).Thisdifferencewasdetectable at
Week 2 following HLI (28+5.6 vs. 58.3+10.0, P¼ 0.006, Figure 1A) and
persisted until Week 5 (43.9+5.5 vs. 59.2+6.1, P ¼ 0.02, Figure 1A). At
5-week post-HLI, untreated Type 1 DM mice showed a lower capillary
density compared with non-diabetic controls (0.93+0.06 vs. 1.46+
0.12, n ¼ 5 and 7, respectively; P ¼ 0.006, Figure 1B). We obtained a
similar result with alkaline phosphatase staining (0.55+0.1 vs. 0.86+
0.14, n ¼ 4 and 5, respectively, P ¼ 0.02). These results are consistent
with prior studies using different models of Type 1 diabetes.10
3.2 Impaired VEGFR2 expression in
non-ischaemic and Day 3 post-ischaemic
mouse hind limb muscles despite similar
capillary density in Type 1 DM compared
with non-DM controls
We analysed the expression of VEGFR2 in non-ischaemic and Day 3
post-ischaemic (a time point where the perfusion recovery was compar-
able between the groups) hind limb muscles of untreated Type 1 DM
mice and non-diabetic controls. Our results showed 30% less VEGFR2
proteinexpression inuntreatedType1DMnon-ischaemichind limbscom-
pared with non-diabetic controls (0.34+0.02 vs. 0.47+0.04 ng/mg total
protein, P¼ 0.02, n ¼ 6 and 7, respectively, Figure 2A). We also found
50% less VEGFR2 expression in Day 3 post-ischaemic hind limbs of un-
treated Type 1 DM mice compared with non-diabetic controls (0.50+
0.05 vs. 0.89+0.09 ng/mg of total protein, n ¼ 5 and 6, respectively,
P ¼ 0.01, Figure 2B). Next, we assessed whether the difference in
VEGFR2 expression was due to a difference in capillary density between
non-ischaemic hind limbs of untreated Type 1 DM compared with non-
diabetic controls. Our results showed no difference in capillary density
between the two groups (Figure 2C). We also found no difference in capil-
lary density when we compared Day 3 post-ischaemic hind limbs from
untreated Type 1 DM and non-diabetic controls (Figure 2D). Next, we
analysed whether there was lower VEGFR2 mRNA expression in the
non-ischaemic and ischaemic hind limb muscles. We found that, in the
non-ischaemic hind limbs from untreated Type 1 DM mice, VEGFR2
mRNA expression was lower compared with that from non-diabetic
mice (Figure 2E). In the ischaemic hind limbs, there was no difference
in VEGFR2 mRNA expression in untreated Type 1 DM mice when com-
pared with non-diabetic controls (Figure 2F). Therefore, in non-ischaemic
hind limb muscles, untreated Type 1 DM mouse showed lower
expression of VEGFR2 compared with non-diabetic controls, likely due
to decreased mRNA transcription, while in the ischaemic hind limbs
decreased VEGFR2 expression does not appear to be from impaired
mRNA expression.
3.3 Treatment of Type 1 DMmice with
insulin results in enhanced perfusion
recovery and increased capillary density
in the ischaemic limb
Mice with Type 1 DM were treated with insulin achieving an Hb1ac of
5.6+0.1 (n ¼ 56), which is consistent with current recommended
Figure 1 Perfusion recovery is impaired in untreated Type 1 DM
mice and associated with decreased capillary density in Week 5 post-
ischaemic (A) impaired perfusion recovery in untreated type 1 diabetes
mellitus (DM1). The Y-axis shows perfusion ischaemic to non-
ischaemic limb normalized to values immediately post-surgery, while
the X-axis shows time post-surgery (Type 1 DM n ¼ 16–17 and ND
control, n ¼ 8, NS ¼ not significant, P . 0.05, *P ¼ 0.006 at W2 and
0.02 at W5). (B) Since maximum perfusion is already achieved at
Week 5post-ischaemia,wecomparedcapillary density inWeek5post-
ischaemic hind limbs from untreated DM1 mice (n ¼ 5) with that from
non-DM controls (n ¼ 7) and found lower capillary density
(*P ¼ 0.006) in untreated DM1 mice at Week 5.
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treatment targets (i.e.Hba1cof ≤ 6.5) for individualwith diabetes.21 We
found no necrosis in the control non-DM and treated Type 1 DM mice
(n ¼ 12 and 21, respectively). Insulin-treated Type 1 DM mice showed
perfusion recovery that was comparable with non-diabetic controls
(change in perfusion at Week 5 for treated Type 1 DM ¼ 55.0+3.8
vs. non-DM ¼ 56.7+4.4, n ¼ 21 and 8–12, respectively, P ¼ 0.6,
Figure 3A). Additionally, treated Type 1 DM mouse hind limb muscle
showed comparable capillary density (by CD31 staining) with non-
diabetic controls at Week 5 post-experimental PAD (1.28+0.1 vs.
1.46+ 0.12, n ¼ 10 and 7, respectively, P ¼ 0.3, Figure 3B). The results
were similar, when capillary density was assessed by the alkaline phos-
phatase method (treated DM ¼ 0.7+0.04 vs. non-DM control ¼
0.9+0.14, n ¼ 6 and 5, respectively, P ¼ 0.2). Hence, treating hypergly-
caemia in Type 1 DM mice improves perfusion recovery and hind limb
capillary density following HLI.
3.4 Effect of treatment with insulin on
VEGFR 2 expression in ischaemic hind
limb muscle
Muscle lysates from Day 3 post-ischaemic hind limbs of treated Type 1
DM, untreated Type 1 DM, and non-diabetic control micewere analysed
for levels of VEGFR2 protein. We found that VEGFR2 protein was ap-
proximately two-fold higher in the treated Type 1 DM mice compared
with the untreated Type 1 DM mice and comparable with the levels in
the non-diabetic control (treated ¼ 2.99+ 0.20 vs. untreated ¼
1.31+0.08, non-diabetic control ¼ 2.34+0.18, n ¼ 7, 6, and 5, re-
spectively. P, 0.0001 for treated vs. untreated and P ¼ 0.07 for
treated vs. non-diabetic controls, Figure 4A). In contrast, the level of
VEGFA protein expression in treated Type 1 DM hind limb muscle
increased comparedwith that in untreatedType1DM, but was not com-
parable with that in non-diabetic controls (non-diabetic control ¼
30.7+1.1, n ¼ 10, untreated ¼ 17.2+ 0.5, n ¼ 8, and treated ¼
22.4+1.2, n ¼ 11, VEGFA pg/mg total protein, P, 0.01 in all, see Sup-
plementary material online, Figure S1D). We compared VEGFR2 mRNA
levels in Day 3 post-ischaemic hind limb muscles of treated Type 1 DM,
untreated Type 1 DM, and non-diabetic control mice. We found no dif-
ference in VEGFR2 mRNA expression among the three groups com-
pared (Figure 4B). This suggests that the increased VEGFR2 protein
expression in Day 3 post-ischaemic hind limbs of treated Type 1 DM
mice likely lies at the post-transcription level.
3.5 Role of VEGFR2 in perfusion recovery
in insulin-treated DM1mice
We administered a VEGFR2-neutralizing antibody22 into treated Type 1
DM mice and followed perfusion after HLI. Our results showed that
administering a VEGFR2-neutralizing antibody resulted in impaired
Figure2 VEGFR2 expression is impaired in non-ischaemic and Day 3 ischaemic hind limbs of untreated Type 1 DM mice. (A) In non-ischaemic hind limbs,
VEGFR2 protein expression is30% less compared with non-DM controls (n ¼ 7, *P ¼ 0.02). (B) In Day 3 ischaemic hind limbs, VEGFR2 protein expres-
sion is 50% less in untreated Type 1 DM (n ¼ 6) compared with non-DM controls (n ¼ 5, *P ¼ 0.01). Capillary density was comparable between un-
treated Type 1 DM and non-DM controls in non-ischaemic (C) (Type 1 DM n ¼ 5, non-DM, n ¼ 7, NS, P ¼ 0.33) and ischaemic (D) hind limbs (Type 1
DM n ¼ 5, non-DM n ¼ 7, NS ¼ P ¼ 0.73). (E) In non-ischaemic hind limbs, VEGFR2 mRNA expression was l in untreated Type 1 DM compared with
non-DM controls (n ¼ 5/grp, P ¼ 0.004) and may account for the decreased VEGFR2 protein. (F ) VEGFR2 mRNA in Day 3 ischaemic hind limbs
(n ¼ 4) was not impaired, but comparable with non-DM controls (n ¼ 5, NS, P ¼ 0.44).
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perfusion recovery in treated Type 1 DM mice. This effect was present
starting at Week 2 post-HLI and persisted until the end of the experi-
ment at Week 5 (Figure 4C). Of note, treated Type 1 DM mice that
received control antibody showed no impairment in perfusion recovery
(Figure 4D). Therefore, these findings show that improved perfusion re-
covery in treated type 1 diabetes mellitus (DM1) mice is mediated at
least in part through VEGFR2. Next, we assessed which cell types in
the mouse ischaemic hind limbs were expressing VEGFR2 by immunos-
taining of frozen sections of the mouse hind limbs. We found that posi-
tive VEGFR2 staining was found primarily in endothelial (CD31+) cells
(Figure 4E).
3.6 High glucose is sufficient to impair
human endothelial cell VEGFR2 expression
in simulated ischaemia
Next, we sought to determine whether high glucose is sufficient to
impair endothelial cell VEGFR2 expression in simulated ischaemia.
We cultured HUVECS at the same passage number in normal
(5 mmol/L) glucose, in increasing concentrations of D-glucose, and in
L-glucose (at 15, 25, and 50 mmol/L) then exposed the cells to simulated
ischaemia.19 L-glucose provides the same osmolarity, but is not metabo-
lized by the cells. Our results show glucose concentration-dependent
impairment in VEGFR2 expression with peak impairment at 25 mmol/
L of glucose (see Supplementary material online, Figure S1). Next, we
assessed whether high glucose impaired VEGFR2 expression in ischae-
mia by impairing its mRNA synthesis. HUVECS were cultured in
normal (5 mmol/l) or high glucose (25 mmol/l), then exposed to 24 h
of simulated ischaemia; followed by assessment of VEGFR2 protein
and mRNA expression. We found that VEGFR2 protein expression
was impaired in HUVECS cultured in high glucose (Figure 5A and B) com-
pared with those cultured in normal glucose. However, culture in high
glucose did not impair VEGFR2 mRNA expression in HUVECS, as
mRNA levels were similar between cells cultured in high and normal
glucose (Figure 5C ). Therefore, high glucose is sufficient to impair
VEGFR2 expression in simulated ischaemia, and this was not due to
impaired mRNA expression but is likely to be at the post-translational
level.
3.7 Effect of insulin on endothelial cell
VEGFR2 expression
In vivo, control of hyperglycaemia with insulin corrected the impaired
VEGFR2 expression in ischaemic hind limbs of mice with Type 1
DM. This could be due to a direct effect of insulin on endothelial
VEGFR2 expression, or alternatively it could be due to correcting
hyperglycaemia.
Therefore, we sought to determine the effects of insulin on endothe-
lial cell VEGFR2 expression in simulated ischaemia. HUVECS, cultured in
media containing different doses of insulin (1, 10, and 100 nmol/L), prior
to exposure to simulated ischaemia for 24–72 h were analysed for
VEGFR2 expression. We found that insulin did not increase VEGFR2
protein expression at any of the doses or time points assessed (data
shown for 10 nmol/L of insulin at 72 h, Figure 5D and E). To determine
whether insulin treatment can protect HUVECS grown in high glucose
from impaired VEGFR2 expression in ischaemia, the above experiment
was repeated with HUVECS cultured in 15 and 25 mM glucose. Insulin
was not protective, as VEGFR2 expression was still impaired in a dose-
dependent manner in the presence of insulin (see Supplementary mater-
ial online, Figure S1C, data shown for 10 nm insulin but identical results
observed with 100 nM).
3.8 High glucose increases VEGFR2
ubiquitination and degradation via the
ubiquitin–proteasome complex
Studies have implicated the ubiquitin–proteasome system in the regula-
tion of VEGFR2 expression following VEGFA binding.23 Additionally,
there is evidence that hyperglycaemia may increase proteasome-
mediated degradation of proteins.24 We therefore hypothesized that
increased degradation of VEGFR2 via the ubiquitin–proteasome
system may account for decreased endothelial cell expression of
VEGFR2 in hyperglycaemia and ischaemia. We analysed the extent of
VEGFR2 ubiquitination in HUVECS cultured in either normal or high
glucose before exposure to simulated ischaemia. We found higher
levels of VEGFR2 ubiquitination in HUVECS exposed to high glucose
compared with those exposed to normal glucose (Figure 6A and B, left
panel). In vivo, comparison of VEGFR2 ubiquitination in ischaemic hind
limbs of non-DM and untreated Type 1 DM mice showed higher
Figure3 (A) Perfusion recovery in treated Type 1 DM mice (n ¼ 21)
is comparable with that of non-diabetic controls (n ¼ 8–12). The
Y-axis shows the perfusion ratio (ischaemic-to-non-ischaemic limb)
normalized to values immediately post-surgery. The X-axis shows
the time point at which perfusion was assessed (P. 0.05) at all time
points. (B) Capillary density in Week 5 post-ischaemic hind limb
muscles of treated Type 1 DM mice (n ¼ 10) is comparable with that
of non-diabetic controls (n ¼ 7, NS, P. 0.05).
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Figure 4 Treatment of hyperglycaemia improves VEGFR2 expression in ischaemic hind limb muscles of Type 1 DM mice, and neutralizing VEGFR2
abolishes the treatment-related improved perfusion recovery. (A) A fold increase in VEGFR2 protein is comparable in treated Type 1 DM and non-DM
controls in Day 3 post-ischaemic hind limb muscles, but impaired in untreated Type 1 DM mice (treated Type 1 DM, n ¼ 7; non-DM controls n ¼ 5;
untreated Type 1 DM n ¼ 6, *P, 0.05, NS ¼ not significant, P. 0.05). (B) VEGFR2 mRNA expression by quantitative PCR showed no difference in
the level of expression between non-DM, untreated Type 1 DM, and treated Type 1 DM in Day 3 post-ischaemic hind limbs (n ¼ 6, 7, and 5, respectively,
NS, P. 0.05). (C ) Treatment with a VEGFR2-neutralizing antibody results in impaired perfusion recovery in treated Type 1 DM. The Y-axis shows the
perfusion ratio (ischaemic-to-non-ischaemic limb) normalized to values immediately post-surgery, while the X-axis shows time post-surgery [non-DM
controlsn ¼ 6–7, treated (Tx) type1DMn ¼ 8–10,*P ¼ 0.008at W3and 0.01atW,NS,P ¼ 0.99]. (D)Treatmentwith isotypematchedcontrol antibody
had no effect on perfusion recovery in treated Type 1 DM mice [non-DM controls n ¼ 7, treated (Tx) Type 1 DM n ¼ 5]. (E, F, and G) Immunostaining of
sections from Week 5 post-ischaemic hind limb muscles of non-diabetic control (E), untreated Type 1 DM (F), and Treated Type 1 DM mice (G). It shows
co-localization of VEGFR2 expression with CD31-expressing cells (CD31 ¼ green, VEGFR2 ¼ pink, actin ¼ red, blue ¼ nuclear staining, green + pink ¼
white) consistent with endothelial cell expression.
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ubiquitination in the untreated Type 1 DM (Figure 6A and B, middle
panel). Additionally, comparison of VEGFR2 ubiquitination in ischaemic
hind limbs of treated and untreated Type 1 DM mice showed higher
ubiquitination in the untreated Type 1 DM (Figure 6A and B, right
panel). As positive and negative control, western blotting of lysates of
mouse ischaemic hind limbs was performed and probed with either
the secondary antibody alone or the same anti-poly-ubiquitin antibody
used to probe VEGFR2 IPs. The blot showed a smear consistent with
prior reports23 (see Supplementary material online, Figure S1G, top
panel), while the secondary antibody alone showed no signal (see
Supplementary material online, Figure S1G, bottom panel).
Taken together, our results show that, in hyperglycaemia or high
glucose, there is increased ubiquitination of VEGFR2, and this may
lead to increased proteasome-mediated degradation of VEGFR2. To
assess whether the ubiquitin–proteasome system is involved in the deg-
radation of VEGFR2, HUVECs were pre-treated with different concen-
trations of the proteasome inhibitor, epoxomycin, and then exposed to
simulated ischaemia. We found inhibition of the proteasome complex
with epoxomycin protected against VEGFR2 degradation in a dose-
dependent manner (Figure 6C). The level of VEGFR2 expression in
HUVECS exposed to high glucose but pre-treated with epoxomycin
was similar to those from HUVECS cultured in normal glucose
(Figure 6D and E). Thus, impaired VEGFR2 protein expression in ischae-
mia in the setting of high glucose is likely due to increased degradation of
VEGFR2 via the ubiquitin–proteasome system.
4. Discussion
Diabetes is well known to have adverse effects on the clinical course of
patients with PAD.4 In pre-clinical models of PAD, the presence of DM
was associated with worse outcomes (Table 1). However, the mechan-
ism involved in the impaired perfusion recovery and the effects of gly-
caemic control with insulin was poorly understood. To our
knowledge, our study provides the first evidence that in mice with
Figure5 Hyperglycaemia impairs VEGFR2 expression in simulated ischaemia (hypoxia and nutrient deprivation) without altering its mRNA expression.
(A) In simulated ischaemia, VEGFR2 protein expression is impaired in HUVECS pre-cultured in high glucose (25 mM or H Gluc) compared with HUVECS
cultured in normal glucose (5 mM or N Gluc). (B) Quantization of the bands in A, n ¼ 5/grp, **P, 0.01. (E) In simulated ischaemia, VEGFR2 mRNA by
quantitative RT-PCR showed normal expression in HUVECS cultured in high glucose prior to simulated ischaemia exposure (n ¼ 6/grp, NS ¼ not signifi-
cant, P ¼ 0.33). (D) Insulin treatment did not increase VEGFR2 expression in HUVECs. Cells were cultured in the presence or absence of insulin, and then
exposed to simulated ischaemia for 12, 24, 48, and 72 h following an initial overnight starvation in insulin and growth factor-free medium. A representative
western blot of VEGFR2 expression following treatment with 10 nM of insulin at 72 h is shown. (E) Quantization of the blot in D (n ¼ 3/grp, NS ¼ not
significant, P . 0.05).
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Type 1 DM controlling hyperglycaemia to current clinically recom-
mended Hb1ac targets normalizes perfusion recovery following HLI
and this was associated with modulation of VEGFR2 expression in is-
chaemic endothelium.
In the previous studies, proposed mechanisms of impaired perfusion
recovery following HLI in mice with DM include: accumulation of
advanced glycation end products, generation of reactive oxygen
species, decreased bone marrow mononuclear cells, impaired endothe-
lial progenitor cell mobilization, increased inflammation, impaired HIF-1
alpha expression, and alterations in the expression of VEGF, impaired
platelet derived growth factor C (PDGF-C), and neuropilin 1 and neu-
ropilin 2 expression (summarized in Table 1). While impaired VEGFA
expression in Type 1 DM mice has been shown to contribute to poor
perfusion recovery following HLI,8,10,11 less is known about the role of
VEGF receptors. VEGFR2 is the dominant VEGF receptor involved in
post-natal angiogenesis,15,16 and hence its modulation by hypergly-
caemia in Type 1 DM is a likely candidate to impair perfusion recovery.
Here, we show that VEGFR2 expression is impaired in non-ischaemic
and ischaemic hind limb muscles of mice with Type 1 DM. In the ischae-
mic hind limbs, despite comparable capillary densities at Day 3 following
HLI, VEGFR2 expression was decreased in untreated Type 1 DM hind
limbs compared with non-diabetic controls. This shows lower expres-
sion of VEGFR2 even when adjusting for capillary content. Recent
studies by Moriya et al.13 showed that PDGF-C but not VEGFA vector
injection improved perfusion recovery in streptozotocin-induced
Type 1 DM following HLI. The role of VEGFR2 in the lack of VEGFA ef-
ficacy was not assessed in that study and although the lack of efficacy of
VEGFA could be due to a number of factors, impaired VEGFR2 expres-
sion as shown in our study is likely to be a contributing factor.
Improved VEGFR2 expression in hind limb muscles of insulin-treated
Type 1 DM mice may have been due to the glucose-lowering effect of
insulin or due to a direct effect of insulin on VEGFR2 expressing cells.
As expected, we showed that VEGFR2 expression was primarily on
endothelial cells in muscle in vivo. To more easily separate the effects
of insulin and glucose, we moved to an in vitro system. In vitro, we
showed that high glucose was sufficient to impair endothelial VEGFR2
Figure 6 (A) VEGFR2 immunoprecipitation followed by anti-ubiquitin western blotting reveals higher VEGFR2 ubiquitination in HUVECs exposed to
simulated ischaemia in the setting of high glucose compared with those in the setting of normal glucose (left panel). In vivo, VEGFR2 ubiquitination is higher in
ischaemic hind limbs fromType 1DM mice (middle panel). Insulin treatment results in reducedVEGFR2 ubiquitination in ischaemic hind limbs of Type 1 DM
(Tx Type 1 DM, right panel). (B) Ubiquitin-to-VEGFR2 ratio from quantization of VEGFR2 band represented inA (left panel, n ¼ 3 for N glucose and 4 for H
glucose, ***P ¼ 0.006; middle panel, n ¼ 3 for non-DM and 4 for Type 1 DM, *P ¼ 0.01; right panel, n ¼ 5 for Type 1 DM and 4 for Tx Type 1 DM,
*P ¼ 0.04). (C) Blocking ubiquitin–proteasome degradation with epoxomycin restores VEGFR2 expression in simulated ischaemia in a dose-dependent
manner. (D) Representative blot showing VEGFR2 expression in simulated ischaemia restored with epoxomycin treatment. (E) Quantification of the bands
in D (N Gluc ¼ normal glucose, H Gluc ¼ high glucose, Epo ¼ epoxomycin, n ¼ 3, *P, 0.05, NS ¼ not significant). Each blot is representative of at least
three experiments.
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expression in simulated ischaemia. Insulin treatment of endothelial cells
did not increase VEGFR2 expression nor did it protect against impaired
VEGFR2 expression in high glucose in the setting of simulated ischaemia.
Although we cannot exclude the possibility that insulin has other effects
that contribute to improved perfusion recovery in vivo, our data clearly
show that insulin has no effect on improving endothelial cell VEGFR2 ex-
pression. Therefore, it is more likely that the improved VEGFR2 expres-
sion was due to the glucose-lowering effect of insulin rather than a direct
effect of insulin on endothelial VEGFR2 expression in ischaemia. Finally,
in vivo, systemic delivery of a VEGFR2-neutralizing antibody was suffi-
cient to block perfusion recovery following HLI in the treated Type 1
DM mice, thus confirming a role of VEGFR2 expression in perfusion re-
covery in the insulin-treated Type 1 DM mice. A recent study by Villalta
et al.25 nicely showed that insulitis in the NOD model of Type 1 DM can
be abrogatedby blocking VEGFR2 and consequently delayonset of Type
1 DM. However, the Type 1 DM model (Akita mice) used in our study
develops diabetes as a result of progressive loss of beta cells due to ac-
cumulation of mis-folded Ins 2 protein within the beta cells rather than
through insulitis as seen in NOD mice.26 Additionally, the Akita mice in
our study were already treated with insulin to near-normal glycaemia
(Hba1c 5.6+0.1) prior to injection of VEGFR2 antibody. Therefore,
it is very unlikely that the effect of VEGFR2 blocking antibody used in
our study is through modulation of diabetes.
Meyer et al.23 established a role for ubiquitination and proteasome
degradation in the regulation of VEGFR2 expression. Here, we show
that VEGFR2 is more highly ubiquitinated in untreated Type 1 DM
ischaemic hind limbs and endothelial cells cultured in high glucose and
subjected to simulated ischaemia when compared with controls. More-
over, inhibition of the ubiquitin–proteasome complex restored endo-
thelial cell VEGFR2 levels in simulated ischaemia and high glucose.
Hence, our current studies extend prior findings, by showing that
impaired VEGFR2 expression in ischaemia and high glucose is regulated
by the ubiquitin–proteasome complex and links this to impaired perfu-
sion recovery in Type 1 DM following HLI. While it is likely that other
proteins involved in ischaemic vascular remodelling are also affected
by increased ubiquitination in high glucose, the current study was not
meant to be exhaustive in evaluating all possible proteins affected by
increased ubiquitination. Instead, the goal was to define the effect of
high glucose on VEGFR2, since it is one of the proteins that play a
pivotal role in post-natal angiogenesis.
In conclusion, while glycaemic control is likely to affect more than one
process involved in perfusion recovery following HLI, our current study
provides a framework from which we can begin to understand the po-
tential benefits of glucose normalization as a therapeutic target in PAD.
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